Balance Sheet

Accounts Payables Accumulated Expenses Assets Cash & Current Investments Cash & Equivalents Common Equity Convertible Debt Current Assets Current Deferred Revenue Current Leases Current Taxes Finished Goods Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Long-Term Investments Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deferred Tax Liability Notes Payables Operating Leases Other Non-Current Assets Other Non-Current Liabilities Payables Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Work In Process

Cash Flow Statement

Daily Values

Growth Metrics

Others

Pulmonx (LUNG) Preferred Stock Liabilities (2019 - 2020)

Pulmonx has reported Preferred Stock Liabilities over the past 2 years, most recently at $207.6 million for Q3 2020.

Quarterly Preferred Stock Liabilities rose 1.1% to $207.6 million in Q3 2020 from the year-ago period, while the trailing twelve-month figure was $207.6 million through Sep 2020, up 1.1% year-over-year, with the annual reading at $205.3 million for FY2019, 46.11% up from the prior year.
Preferred Stock Liabilities was $207.6 million for Q3 2020 at Pulmonx, roughly flat from $207.6 million in the prior quarter.
Over five years, Preferred Stock Liabilities peaked at $207.6 million in Q1 2020 and troughed at $205.3 million in Q3 2019.